WO2020118018A1 - Solution collection device with evaluation element - Google Patents

Solution collection device with evaluation element Download PDF

Info

Publication number
WO2020118018A1
WO2020118018A1 PCT/US2019/064623 US2019064623W WO2020118018A1 WO 2020118018 A1 WO2020118018 A1 WO 2020118018A1 US 2019064623 W US2019064623 W US 2019064623W WO 2020118018 A1 WO2020118018 A1 WO 2020118018A1
Authority
WO
WIPO (PCT)
Prior art keywords
blood
housing
fluid
testing device
sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2019/064623
Other languages
French (fr)
Inventor
Jennifer Samproni
Manish Deshpande
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Siemens Healthcare Diagnostics Inc
Original Assignee
Siemens Healthcare Diagnostics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Siemens Healthcare Diagnostics Inc filed Critical Siemens Healthcare Diagnostics Inc
Priority to EP19893876.3A priority Critical patent/EP3890594A4/en
Priority to MX2021006612A priority patent/MX2021006612A/en
Priority to JP2021531951A priority patent/JP2022511512A/en
Priority to CA3122235A priority patent/CA3122235A1/en
Priority to US17/299,816 priority patent/US12332234B2/en
Publication of WO2020118018A1 publication Critical patent/WO2020118018A1/en
Priority to IL283691A priority patent/IL283691A/en
Anticipated expiration legal-status Critical
Priority to US19/214,650 priority patent/US20250283868A1/en
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
    • G01N21/1717—Systems in which incident light is modified in accordance with the properties of the material investigated with a modulation of one or more physical properties of the sample during the optical investigation, e.g. electro-reflectance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/15—Devices for taking samples of blood
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D63/00—Apparatus in general for separation processes using semi-permeable membranes
    • B01D63/08—Flat membrane modules
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D63/00—Apparatus in general for separation processes using semi-permeable membranes
    • B01D63/08—Flat membrane modules
    • B01D63/087—Single membrane modules
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D69/00—Semi-permeable membranes for separation processes or apparatus characterised by their form, structure or properties; Manufacturing processes specially adapted therefor
    • B01D69/08—Hollow fibre membranes
    • B01D69/087—Details relating to the spinning process
    • B01D69/088—Co-extrusion; Co-spinning
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
    • B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
    • B01L3/502—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures
    • B01L3/5023—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures with a sample being transported to, and subsequently stored in an absorbent for analysis
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
    • B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
    • B01L3/508—Rigid containers without fluid transport within
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
    • B01L3/56—Labware specially adapted for transferring fluids
    • B01L3/563—Joints or fittings; Separable fluid transfer means to transfer fluids between at least two containers, e.g. connectors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/01—Arrangements or apparatus for facilitating the optical investigation
    • G01N21/11—Filling or emptying of cuvettes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
    • G01N21/25—Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
    • G01N21/251—Colorimeters; Construction thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/75—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated
    • G01N21/77—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/75—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated
    • G01N21/77—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator
    • G01N21/78—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator producing a change of colour
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N29/00—Investigating or analysing materials by the use of ultrasonic, sonic or infrasonic waves; Visualisation of the interior of objects by transmitting ultrasonic or sonic waves through the object
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G01N33/49—Blood
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G01N33/49—Blood
    • G01N33/4915—Blood using flow cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G01N33/49—Blood
    • G01N33/4925—Blood measuring blood gas content, e.g. O2, CO2, HCO3
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/52—Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper and including single- and multilayer analytical elements
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/14—Details; Accessories therefor
    • A61J1/1406—Septums, pierceable membranes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/14—Details; Accessories therefor
    • A61J1/20—Arrangements for transferring or mixing fluids, e.g. from vial to syringe
    • A61J1/2003—Accessories used in combination with means for transfer or mixing of fluids, e.g. for activating fluid flow, separating fluids, filtering fluid or venting
    • A61J1/2006—Piercing means
    • A61J1/201—Piercing means having one piercing end
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/14—Details; Accessories therefor
    • A61J1/20—Arrangements for transferring or mixing fluids, e.g. from vial to syringe
    • A61J1/2003—Accessories used in combination with means for transfer or mixing of fluids, e.g. for activating fluid flow, separating fluids, filtering fluid or venting
    • A61J1/2048—Connecting means
    • A61J1/2051—Connecting means having tap means, e.g. tap means activated by sliding
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/14—Details; Accessories therefor
    • A61J1/20—Arrangements for transferring or mixing fluids, e.g. from vial to syringe
    • A61J1/2003—Accessories used in combination with means for transfer or mixing of fluids, e.g. for activating fluid flow, separating fluids, filtering fluid or venting
    • A61J1/2079—Filtering means
    • A61J1/2086—Filtering means for fluid filtration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/14—Details; Accessories therefor
    • A61J1/20—Arrangements for transferring or mixing fluids, e.g. from vial to syringe
    • A61J1/2096—Combination of a vial and a syringe for transferring or mixing their contents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2200/00—Solutions for specific problems relating to chemical or physical laboratory apparatus
    • B01L2200/02—Adapting objects or devices to another
    • B01L2200/026—Fluid interfacing between devices or objects, e.g. connectors, inlet details
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2200/00—Solutions for specific problems relating to chemical or physical laboratory apparatus
    • B01L2200/06—Fluid handling related problems
    • B01L2200/0631—Purification arrangements, e.g. solid phase extraction [SPE]
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2200/00—Solutions for specific problems relating to chemical or physical laboratory apparatus
    • B01L2200/06—Fluid handling related problems
    • B01L2200/0684—Venting, avoiding backpressure, avoid gas bubbles
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2200/00—Solutions for specific problems relating to chemical or physical laboratory apparatus
    • B01L2200/06—Fluid handling related problems
    • B01L2200/0689—Sealing
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2200/00—Solutions for specific problems relating to chemical or physical laboratory apparatus
    • B01L2200/10—Integrating sample preparation and analysis in single entity, e.g. lab-on-a-chip concept
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2200/00—Solutions for specific problems relating to chemical or physical laboratory apparatus
    • B01L2200/16—Reagents, handling or storing thereof
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2300/00—Additional constructional details
    • B01L2300/02—Identification, exchange or storage of information
    • B01L2300/021—Identification, e.g. bar codes
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2300/00—Additional constructional details
    • B01L2300/06—Auxiliary integrated devices, integrated components
    • B01L2300/0627—Sensor or part of a sensor is integrated
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2300/00—Additional constructional details
    • B01L2300/06—Auxiliary integrated devices, integrated components
    • B01L2300/0627—Sensor or part of a sensor is integrated
    • B01L2300/0663—Whole sensors
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2300/00—Additional constructional details
    • B01L2300/06—Auxiliary integrated devices, integrated components
    • B01L2300/0681—Filter
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2300/00—Additional constructional details
    • B01L2300/06—Auxiliary integrated devices, integrated components
    • B01L2300/069—Absorbents; Gels to retain a fluid
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2300/00—Additional constructional details
    • B01L2300/08—Geometry, shape and general structure
    • B01L2300/0809—Geometry, shape and general structure rectangular shaped
    • B01L2300/0825—Test strips
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2400/00—Moving or stopping fluids
    • B01L2400/04—Moving fluids with specific forces or mechanical means
    • B01L2400/0403—Moving fluids with specific forces or mechanical means specific forces
    • B01L2400/0406—Moving fluids with specific forces or mechanical means specific forces capillary forces
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2400/00—Moving or stopping fluids
    • B01L2400/04—Moving fluids with specific forces or mechanical means
    • B01L2400/0403—Moving fluids with specific forces or mechanical means specific forces
    • B01L2400/0415—Moving fluids with specific forces or mechanical means specific forces electrical forces, e.g. electrokinetic
    • B01L2400/0424—Dielectrophoretic forces
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2400/00—Moving or stopping fluids
    • B01L2400/04—Moving fluids with specific forces or mechanical means
    • B01L2400/0403—Moving fluids with specific forces or mechanical means specific forces
    • B01L2400/043—Moving fluids with specific forces or mechanical means specific forces magnetic forces
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2400/00—Moving or stopping fluids
    • B01L2400/04—Moving fluids with specific forces or mechanical means
    • B01L2400/0403—Moving fluids with specific forces or mechanical means specific forces
    • B01L2400/0433—Moving fluids with specific forces or mechanical means specific forces vibrational forces
    • B01L2400/0436—Moving fluids with specific forces or mechanical means specific forces vibrational forces acoustic forces, e.g. surface acoustic waves [SAW]
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2400/00—Moving or stopping fluids
    • B01L2400/04—Moving fluids with specific forces or mechanical means
    • B01L2400/0475—Moving fluids with specific forces or mechanical means specific mechanical means and fluid pressure
    • B01L2400/0478—Moving fluids with specific forces or mechanical means specific mechanical means and fluid pressure pistons
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2400/00—Moving or stopping fluids
    • B01L2400/06—Valves, specific forms thereof
    • B01L2400/0633—Valves, specific forms thereof with moving parts
    • B01L2400/065—Valves, specific forms thereof with moving parts sliding valves
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
    • G01N21/1717—Systems in which incident light is modified in accordance with the properties of the material investigated with a modulation of one or more physical properties of the sample during the optical investigation, e.g. electro-reflectance
    • G01N2021/1729—Piezomodulation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/75—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated
    • G01N21/77—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator
    • G01N2021/7756—Sensor type
    • G01N2021/7763—Sample through flow
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/84—Systems specially adapted for particular applications
    • G01N21/8483—Investigating reagent band
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2201/00—Features of devices classified in G01N21/00
    • G01N2201/02—Mechanical
    • G01N2201/022—Casings
    • G01N2201/0221—Portable; cableless; compact; hand-held
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N31/00—Investigating or analysing non-biological materials by the use of the chemical methods specified in the subgroup; Apparatus specially adapted for such methods
    • G01N31/22—Investigating or analysing non-biological materials by the use of the chemical methods specified in the subgroup; Apparatus specially adapted for such methods using chemical indicators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G01N33/48707—Physical analysis of biological material of liquid biological material by electrical means
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G01N33/49—Blood
    • G01N33/491—Blood by separating the blood components

Definitions

  • Point-of-care testing refers generally to medical testing at or near the site of patient care, such as in an emergency room.
  • a desired outcome of such tests is often rapid and accurate lab results to determine a next course of action in the patient care.
  • a number of such point of care tests involve analysis of a blood sample from the patient.
  • the ideal blood sample is pure plasma separated from the source whole blood sample.
  • there are often residual broken blood cells as a result of hemolysis due to imperfections in obtaining the sample from the subject, pre-analytical blood sample handling, and the whole blood separation process. In certain cases, these hemolysed cells can interfere with the integrity of analytical test results.
  • resulting free hemoglobin in the sample may cause interference in a number of tests, thereby leading to a signal reduction, reduced measurement accuracy and precision, or to false positive results at the other end of the spectrum.
  • the potassium concentration in a corresponding sample may increase significantly and cause a high risk of misdiagnosis in a diagnostic test for potassium levels.
  • Drabkin's Reagent comprises a mixture that works by lysing red blood cells and quantitatively converting all Hb in a sample into one form, cyanomethaemoglobin, which is then be measured on a spectrometer using a single wavelength. As such, Drabkin's Reagent measures intracellular hemoglobin as well as free hemoglobin. For at least this reason, Drabkin's Reagent does not provide a realistic picture of the extent of free Hb present at a particular point in time in a sample, which is indicative of hemolysis.
  • Figure 1 is a cross sectional view of a portion of a blood testing device constructed in accordance with one embodiment of the present disclosure containing a blood sample.
  • Figure 2 is a cross sectional view of a portion of the blood testing device of Figure 1 showing a sample of acoustically treated blood in accordance with one embodiment of the present disclosure in which blood cells and plasma within a blood sample are separated into a first zone containing plasma and blood cells, and a second zone containing plasma and being substantially devoid of blood cells.
  • Figure 3 is an orthogonal view of a fluid collection device having an integrated blood testing device constructed in accordance with the present disclosure.
  • Figures 4A-4C illustrate views of portions of another version of a fluid collection device constructed in accordance with the present disclosure.
  • Figure 5A illustrates a fluid housing of Figure 4 being inserted into a slot of a reader for acoustic treatment and colorimetric analysis in accordance with one embodiment of the present disclosure.
  • Figure 5B illustrates the fluid housing of Figure 4 being inserted into a port of another version of a reader for acoustic treatment and colorimetric analysis in accordance with one embodiment of the present disclosure.
  • Figure 6 illustrates an exploded, perspective view of a blood testing device removably attachable to a fluid housing such as a syringe constructed in accordance with one embodiment of the present disclosure.
  • Figure 7 illustrates a perspective view of another version of a blood testing device constructed in accordance with one embodiment of the present disclosure.
  • Figure 8 illustrates top plan view of a blood testing device constructed in accordance with one embodiment of the present disclosure.
  • Figure 9 illustrates an exploded, perspective view of a blood testing device removably attachable to a fluid housing such as a syringe constructed in accordance with one embodiment of the present disclosure.
  • Figure 10 illustrates a perspective view of another version of a blood testing device constructed in accordance with one embodiment of the present disclosure.
  • Figure 1 1 illustrates a perspective view of a blood testing device having a closeable gate constructed in accordance with one embodiment of the present disclosure.
  • Figure 12 illustrates a cross-sectional view of the blood testing device of Figure 1 1 having the closeable gate in a first position, and positioned within a slot of a reader in accordance with the present disclosure.
  • Figure 13 illustrates another cross-sectional view of the blood testing device of Figure 1 1 having the closeable gate in a second position, and positioned within the slot of the reader in accordance with the present disclosure.
  • Figure 14 illustrates a perspective view of another version of a blood testing device having a moveable gate constructed in accordance with one embodiment of the present disclosure.
  • Figure 15 illustrates a cross-sectional view of the blood testing device of Figure 14 having the moveable gate in a first position, and positioned within a slot of the reader in accordance with the present disclosure.
  • Figure 16 illustrates another cross-sectional view of the blood testing device of Figure 14 having the moveable gate in a second position, and positioned within the slot of the reader in accordance with the present disclosure.
  • the terms “comprises,” “comprising,” “includes,” “including,” “has,” “having” or any other variation thereof, are intended to cover a non-exclusive inclusion.
  • a process, method, article, or apparatus that comprises a list of elements is not necessarily limited to only those elements, but may include other elements not expressly listed or inherent to such process, method, article, or apparatus.
  • "or” refers to an inclusive or and not to an exclusive or. For example, a condition A or B is satisfied by any one of the following: A is true (or present) and B is false (or not present), A is false (or not present) and B is true (or present), and both A and B are true (or present).
  • any reference to "one embodiment” or “an embodiment” means that a particular element, feature, structure, or characteristic described in connection with the embodiment is included in at least one embodiment.
  • Circuitry may be analog and/or digital, components, or one or more suitably programmed microprocessors and associated hardware and software, or hardwired logic. Also, “components” may perform one or more functions.
  • the term “component,” may include hardware, such as a processor, an application specific integrated circuit (ASIC), or a field programmable gate array (FPGA), or a combination of hardware and software.
  • Software includes one or more computer executable instructions that when executed by one or more component cause the component to perform a specified function. It should be understood that the algorithms described herein are stored on one or more non-transitory memory. Exemplary non-transitory memory includes random access memory, read only memory, flash memory or the like. Such non-transitory memory may be electrically based or optically based.
  • the term“substantially” means that the subsequently described parameter, event, or circumstance completely occurs or that the subsequently described parameter, event, or circumstance occurs to a great extent or degree.
  • the term “substantially” means that the subsequently described parameter, event, or circumstance occurs at least 90% of the time, or at least 91 %, or at least 92%, or at least 93%, or at least 94%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99%, of the time, or means that the dimension or measurement is within at least 90%, or at least 91 %, or at least 92%, or at least 93%, or at least 94%, or at least 95%, or at least 96%, or at least
  • devices, systems, and processes for determining a presence of hemolysis in a sample determine whether hemolysis has occurred in a sample based upon a colorimetry assessment of a portion of the sample.
  • blood collection devices, systems, accessories and processes having a plasma separating feature.
  • the blood testing device 10 includes a housing 12, an acoustic transducer 16, a reader 18, and a control unit 20 connected to the transducer 16 and the reader 18.
  • the housing 12 is constructed of a fluid impermeable material so that the housing 12 can hold and contain a sample of blood containing blood cells, suspended within plasma.
  • the housing 12 can be a syringe or a vacutainer, for example that can be used for collecting blood and transporting the blood for purposes of testing.
  • the blood may be collected from an animal, such as a human, or a non-human (such as a cat, dog, cow, horse, fish, or the like).
  • the acoustic transducer 16, the reader 18, and the control unit 20 may be located outside of the housing 12 as shown in FIG. 1 or inside the housing 12 (not shown).
  • the acoustic transducer 16 selectively generates acoustic forces that are directed to the housing 12.
  • the acoustic transducer 16 can be tuned so as to provide a magnitude and/or frequency of acoustic forces so as to facilitate separation of the undamaged blood cells from the plasma and damaged blood cells.
  • the magnitude and/or frequency of the acoustic forces generated by the acoustic transducer 16 can be selected depending upon a size and/or construction of the housing 12, or composition of the blood sample within the housing 12.
  • the acoustic transducer 16 can be a piezoelectric element. At least a portion of the housing 12, adjacent to the transducer 16, is constructed of a material that functions to pass the acoustic forces generated by the acoustic transducer 16 into the sample contained within the housing 12. Exemplary materials that can be used to form the housing 12 include glass, crystal, and the like. Parts of the housing
  • the application of the acoustic forces into the sample by the acoustic transducer 16 causes the blood cells within the blood to move within the plasma to form a first zone
  • the reader 18 is positioned adjacent to the second zone 24 and functions to read at least one parameter of the plasma.
  • the reader 18 is an optical reader, such as a camera or photospectrometer having a field of view overlapping with the housing 12 such that the plasma within the second zone is visible to the reader 18.
  • the optical reader 18 is positioned such that the second zone 24 is within the field of view.
  • the control unit 20 selectively actuates / deactuates the acoustic transducer 16 to cause separation of the blood cells and plasma into the first zone 22 and the second zone 24. Then, in some embodiments, the control unit 20 actuates the reader 18 to capture information indicative of at least one parameter of the plasma. The information captured by the reader 18 is then transferred to the control unit 20 to determine a degree of hemolysis within the sample of blood.
  • the control unit 20 can be constructed of circuitry and/or a combination of circuitry and software.
  • the degree of hemolysis can be determined by the control unit 20 based upon a colorimetric analysis of the sample. That is, when the sample is devoid of hemolysis and is illuminated with white light, the plasma will be substantially devoid of any color, i.e., the sample will be transparent. When hemolysis has occurred within the sample, the plasma will be pink when the plasma is illuminated with white light. By correlating the color of the plasma with predetermined colors indicative of an extent of hemolysis occurring within other samples, the extent of hemolysis within the sample can be determined. Depending upon a color of a backdrop, and/or color of illumination of the plasma, colors detected by the reader 18 indicative of an extent of hemolysis may differ.
  • Information indicative of an extent of hemolysis within the sample can be used to determine whether the blood has hemolysis.
  • FIG. 3 illustrates a blood testing device 40 constructed in accordance with one embodiment of the present disclosure.
  • the blood testing device 40 is provided with a fluid container such as a syringe 42 or vacutainer having a fluid reservoir 44 for containing blood.
  • the blood testing device 40 may also be provided with an acoustic transducer 46, an optical zone 48, and a bar code 50 which identifies the contents of the syringe 42 and can be correlated to specific patients.
  • the acoustic transducer 46 may be provided with any suitable shape, such as planar, arcuate, or the like.
  • the acoustic transducer 46 may be provided with a shape to match a shape of the optical zone 48, or other section of the blood testing device 40 to be stimulated by the acoustic transducer 46.
  • the blood testing device 40 allows the blood to be acoustically treated using the acoustic transducer 46 after which the blood may be analyzed using an optical reader or the human eye through the optical zone 48. Once a degree of hemolysis within the sample of blood has been determined, a decision can be made whether or not to continue with further testing of the sample of blood.
  • the blood testing device 70 has a fluid housing 72, a fluid reservoir 74, a fluid treatment area 75, an optical zone 76, a treatment window 78, and a flow port 82.
  • the reader 71 has a reading device 80, a flow path 82, and an analysis unit 84.
  • a blood sample is contained in the fluid housing 72 and directed along the flow path 82 into the fluid treatment area 75 where the blood sample is directed to flow past the treatment window 78.
  • the treatment window 78 is constructed of a material that functions to pass acoustic forces generated by an acoustic transducer into the blood sample contained within the fluid housing 72.
  • the reading device 80 is part of the analysis unit 84 and is provided with an acoustic transducer (not shown) and an optical reader (not shown) which operate as described above to acoustically treat the blood sample.
  • the acoustic transducer may be provided with a planar shape so as to mate with the treatment window 78 of the blood testing device 70.
  • the optical reader of the reading device 80 has a field of view directed to the optical zone 76 where the acoustically treated blood sample may be read.
  • the analysis unit 84 actuates the acoustic transducer to acoustically treat the blood sample and move the blood cells away from the optical zone 76 such that only the plasma is visible in the optical zone 76.
  • the analysis unit 84 may be provided with further blood analysis features (not shown) such as blood gas analysis which may further analyze the blood sample after it passes through the flow path 82.
  • the reader 71 may be portable and have a housing 88 that includes a slot 90 sized and dimensioned to receive the blood testing device 70 such that the optical zone 76 is in the field of view of the optical reader and the treatment window overlaps with the acoustic transducer.
  • the housing 88 can be provided in a variety of shapes such as in a shape of a hot dog bun, for instance.
  • the analysis unit 84 can be supported in the housing 88 or be separate therefrom.
  • the reading device 80 can be provided with a wireless transceiver to communicate with the analysis unit 84.
  • the analysis unit 84 may be constructed and function in a similar manner as the control unit 20 discussed above.
  • Figure 5 illustrates another variation of the reader 71 in which the fluid housing 72 of Figure 4 may be inserted into the housing 88 so that the blood sample may be acoustically treated and read by the reading device 80 as described above.
  • a lateral flow blood testing device 100 constructed in accordance with the present disclosure is shown having a fluid housing 102, a first fluid reservoir 104, and a fluid treatment module 106.
  • the fluid treatment module 106 of the lateral flow blood testing device 100 is provided with a lower portion 108, an upper portion 1 10, a second fluid reservoir 1 1 1 , a lateral flow strip 1 12, a fluid channel 1 14, a first fluid port 1 16, a second fluid port 1 18, an optical zone 120, and a bar code 122.
  • the lower portion 108 and the upper portion 1 10 of the fluid treatment module 106 are sealably connected to form the second fluid reservoir 1 1 1.
  • a blood sample may be transferred from the first fluid reservoir 104 to the second fluid reservoir 1 1 1.
  • a portion of the blood sample may be directed through the second fluid port 1 18 into the fluid channel 1 14 where the blood sample passes through the lateral flow strip 1 12.
  • capillary action which may also be referred to as capillary flow
  • the lateral flow strip 1 12 causes the separation of undamaged blood cells and plasma in the blood sample as described more fully in U.S. Patent Application No. 15/317,748, the entirety of which is incorporated herein by reference.
  • the plasma that has passed through the lateral flow strip 1 12 may then be analyzed in the optical zone 120 to determine a degree of hemolysis using an optical reader as described above or human eyes.
  • the first fluid port 1 16 may be temporarily sealed using a removable cap (not shown), for instance, that temporarily prevents movement of the blood sample through the first fluid port 1 16.
  • a removable cap (not shown), for instance, that temporarily prevents movement of the blood sample through the first fluid port 1 16.
  • the cap may be removed and the blood sample may be allowed to pass through the first fluid port 1 16 to be used for further testing, for instance, as desired.
  • the bar code 122 may be used to identify the blood sample, the patient the blood sample belongs too, the test to be performed, and the like.
  • Figure 7 illustrates a lateral flow blood testing device 140 having a fluid housing 142, a fluid treatment module 144, a first fluid reservoir 146, and a second fluid reservoir 148.
  • the lateral flow blood testing device 140 is similar to the lateral flow blood testing device 100 described above, therefore, in the interest of brevity only the differences will be described herein.
  • the fluid treatment module 144 and the fluid housing 142 are integrated to form the lateral flow blood testing device 140.
  • Figure 8 illustrates a top plan view of a fluid treatment module 160 similar to fluid treatment modules 106 and 144.
  • the fluid treatment module 160 is provided with a fluid channel 162 that connects a first fluid port 164 with a second fluid port 166 to direct a flow of a blood sample into a fluid channel 168 for separation of the blood sample into at least two constituent parts as described above.
  • the fluid channel 168 houses the lateral flow strip 1 12 that functions to separate the undamaged blood cells from the plasma so that the plasma and any color caused by damaged blood cells is visible in the optical zone 120.
  • a lateral flow blood testing device 180 having a fluid housing 182, a fluid reservoir 184, and a fluid treatment module 186.
  • the fluid treatment module 186 of the lateral flow blood testing device 180 is provided with a lower portion 188, an upper portion 190, a second fluid reservoir 192, and a lateral flow membrane 194.
  • the lower portion 188 and the upper portion 190 of the fluid treatment module 186 are sealably connected to form the second fluid reservoir 192.
  • a blood sample may be transferred from the first fluid reservoir 184 to the second fluid reservoir 192.
  • the blood sample passes through the lateral flow membrane 194 and the blood sample is separated into at least two constituent parts, i.e., undamaged blood cells remain in the first fluid reservoir 184 and plasma with any damaged blood cells pass through the lateral flow membrane 194 and into the second fluid reservoir 192.
  • At least the lower portion 188 of the fluid treatment module 186 is constructed of an optically clear material which allows the plasma that has passed through the lateral flow membrane 194 to be colorimetrically analyzed in the second fluid reservoir 192 using an optical reader as described above or human eyes.
  • a probe 196 which may be attached to or part of a blood analysis machine (not shown) such as a blood gas analyzer. Where whole blood is needed for analysis, the probe 196 may be passed through a fluid port 198 in the fluid treatment module 186, through the second fluid reservoir 192, and through the lateral flow membrane 194 into the first fluid reservoir 184 where the blood sample has not been separated.
  • a blood analysis machine such as a blood gas analyzer.
  • Figure 10 illustrates another version of a lateral flow blood testing device 200 having a fluid housing 202, a fluid treatment module 204, a first fluid reservoir 206, a second fluid reservoir 208, a lateral flow membrane 210, and a fluid port 214.
  • the lateral flow blood testing device 200 is similar to the lateral flow blood testing device 180 described above, therefore, in the interest of brevity only the differences will be described herein.
  • the fluid treatment module 204 and the fluid housing 202 are integrated into a unitary structure, rather than removably connected to form the lateral flow blood testing device 200.
  • a probe 212 is also shown which may be attached to or part of a blood analysis machine (not shown) such as a blood gas analyzer. Where whole
  • the probe 212 may be passed through the fluid port 214 in the fluid treatment module 204, through the second fluid reservoir 206, and through the lateral flow membrane 210 into the first fluid reservoir 206 where the blood sample has not been separated.
  • FIG. 1 13 shown therein is yet another version of a blood testing device 240 similar to the blood testing device 70 shown in Figure 4 that can be read by the reader 71.
  • the blood testing device 240 is provided with a fluid housing 242 a fluid reservoir 244, a fluid treatment area 245, an optical zone 246, a treatment window 248, a flow path 252, a gate 254 having a port 256, and a gate guide channel 258.
  • the gate 254 When the gate 254 is in a first position (shown in Figure 12), the flow path 252 is restricted such that a blood sample in the flow path 252 stops in the optical zone 246 where the sample may be acoustically treated to move undamaged blood cells away from the plasma adjacent to the optical zone 246 and read with the reader 71 as described above. [0057] Once the blood sample has been analyzed the gate 254 may be moved to a second position (shown in Figure 13), which moves the port 256 into the flow path 252 allowing the blood sample to pass.
  • FIG. 14-16 shown therein is yet another version of a blood testing device 280 similar to the blood testing devices 70 and 240 shown in Figures 4 and 1 1-13, respectively that can be read by the reader 71.
  • the blood testing device 280 is provided with a fluid housing 282 a fluid reservoir 284, a fluid treatment area 285, an optical zone 286, a treatment window 288, a first flow path 292, a second flow path 294, a gate 296 having a port 298, and a gate guide channel 300.
  • a blood sample is directed into the first flow path 292 such that the blood sample stops in the optical zone 286 where the blood sample may be acoustically treated and read with the reading device 80 as described above.
  • the gate 296 may be moved to a second position (shown in Figure 16), which moves the port 298 into the second flow path 294 allowing the blood sample to pass through the second flow path 294.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ecology (AREA)
  • Clinical Laboratory Science (AREA)
  • Plasma & Fusion (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medical Informatics (AREA)
  • Surgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Investigating Or Analysing Materials By Optical Means (AREA)
  • Sampling And Sample Adjustment (AREA)

Abstract

A blood testing device for detecting hemolysis in a blood sample is described. The blood testing device comprises an housing for containing the blood sample. The housing has a treatment window and an optical zone formed therein. The blood testing device further includes an acoustic transducer positioned to selectively generate acoustic forces directed into the treatment window of the housing and a control unit for selectively actuating and deactuating the acoustic transducer to permit colorimetric analysis of plasma within the blood sample.

Description

SOLUTION COLLECTION DEVICE WITH EVALUATION ELEMENT
[001] The subject application claims benefit under 35 USC § 1 19(e) of US provisional Application No. 62/776,825, filed December 7, 2018. The entire contents of the above-referenced patent application are hereby expressly incorporated herein by reference.
Statement regarding Federally Sponsored Research and Development
[002] Not Applicable.
Background
[003] Point-of-care testing refers generally to medical testing at or near the site of patient care, such as in an emergency room. A desired outcome of such tests is often rapid and accurate lab results to determine a next course of action in the patient care. A number of such point of care tests involve analysis of a blood sample from the patient. The ideal blood sample is pure plasma separated from the source whole blood sample. However, even in such plasma samples, there are often residual broken blood cells as a result of hemolysis due to imperfections in obtaining the sample from the subject, pre-analytical blood sample handling, and the whole blood separation process. In certain cases, these hemolysed cells can interfere with the integrity of analytical test results.
[004] For example, if hemolysis occurs, resulting free hemoglobin in the sample may cause interference in a number of tests, thereby leading to a signal reduction, reduced measurement accuracy and precision, or to false positive results at the other end of the spectrum. For one, it has been found that the potassium concentration in a corresponding sample may increase significantly and cause a high risk of misdiagnosis in a diagnostic test for potassium levels.
[005] To determine whether hemolysis has occurred, a number of tests have been developed to determine hemoglobin (Hb) levels in a blood sample. One common reagent used for determining Hb levels or hemolysis in a blood sample is referred to as Drabkin's Reagent. Drabkin's Reagent comprises a mixture that works by lysing red blood cells and quantitatively converting all Hb in a sample into one form, cyanomethaemoglobin, which is then be measured on a spectrometer using a single wavelength. As such, Drabkin's Reagent measures intracellular hemoglobin as well as free hemoglobin. For at least this reason, Drabkin's Reagent does not provide a realistic picture of the extent of free Hb present at a particular point in time in a sample, which is indicative of hemolysis.
[006] A need exists, therefore, for rapid, point-of-care testing of a blood sample to determine whether hemolysis has occurred that overcomes the shortcomings of the present testing regimes.
BRIEF DESCRIPTION OF THE DRAWINGS
[007] The accompanying drawings, which are incorporated in and constitute a part of this specification, illustrate one or more implementations described herein and, together with the description, explain these implementations. In the drawings:
[008] Figure 1 is a cross sectional view of a portion of a blood testing device constructed in accordance with one embodiment of the present disclosure containing a blood sample. [009] Figure 2 is a cross sectional view of a portion of the blood testing device of Figure 1 showing a sample of acoustically treated blood in accordance with one embodiment of the present disclosure in which blood cells and plasma within a blood sample are separated into a first zone containing plasma and blood cells, and a second zone containing plasma and being substantially devoid of blood cells.
[0010] Figure 3 is an orthogonal view of a fluid collection device having an integrated blood testing device constructed in accordance with the present disclosure.
[0011] Figures 4A-4C illustrate views of portions of another version of a fluid collection device constructed in accordance with the present disclosure.
[0012] Figure 5A illustrates a fluid housing of Figure 4 being inserted into a slot of a reader for acoustic treatment and colorimetric analysis in accordance with one embodiment of the present disclosure.
[0013] Figure 5B illustrates the fluid housing of Figure 4 being inserted into a port of another version of a reader for acoustic treatment and colorimetric analysis in accordance with one embodiment of the present disclosure.
[0014] Figure 6 illustrates an exploded, perspective view of a blood testing device removably attachable to a fluid housing such as a syringe constructed in accordance with one embodiment of the present disclosure.
[0015] Figure 7 illustrates a perspective view of another version of a blood testing device constructed in accordance with one embodiment of the present disclosure.
[0016] Figure 8 illustrates top plan view of a blood testing device constructed in accordance with one embodiment of the present disclosure. [0017] Figure 9 illustrates an exploded, perspective view of a blood testing device removably attachable to a fluid housing such as a syringe constructed in accordance with one embodiment of the present disclosure.
[0018] Figure 10 illustrates a perspective view of another version of a blood testing device constructed in accordance with one embodiment of the present disclosure.
[0019] Figure 1 1 illustrates a perspective view of a blood testing device having a closeable gate constructed in accordance with one embodiment of the present disclosure.
[0020] Figure 12 illustrates a cross-sectional view of the blood testing device of Figure 1 1 having the closeable gate in a first position, and positioned within a slot of a reader in accordance with the present disclosure.
[0021] Figure 13 illustrates another cross-sectional view of the blood testing device of Figure 1 1 having the closeable gate in a second position, and positioned within the slot of the reader in accordance with the present disclosure.
[0022] Figure 14 illustrates a perspective view of another version of a blood testing device having a moveable gate constructed in accordance with one embodiment of the present disclosure.
[0023] Figure 15 illustrates a cross-sectional view of the blood testing device of Figure 14 having the moveable gate in a first position, and positioned within a slot of the reader in accordance with the present disclosure.
[0024] Figure 16 illustrates another cross-sectional view of the blood testing device of Figure 14 having the moveable gate in a second position, and positioned within the slot of the reader in accordance with the present disclosure. DETAILED DESCRIPTION
[0025] The following detailed description refers to the accompanying drawings. The same reference numbers in different drawings may identify the same or similar elements.
[0026] As used herein, the terms "comprises," "comprising," "includes," "including," "has," "having" or any other variation thereof, are intended to cover a non-exclusive inclusion. For example, a process, method, article, or apparatus that comprises a list of elements is not necessarily limited to only those elements, but may include other elements not expressly listed or inherent to such process, method, article, or apparatus. Further, unless expressly stated to the contrary, "or" refers to an inclusive or and not to an exclusive or. For example, a condition A or B is satisfied by any one of the following: A is true (or present) and B is false (or not present), A is false (or not present) and B is true (or present), and both A and B are true (or present).
[0027] In addition, use of the "a" or "an" are employed to describe elements and components of the embodiments herein. This is done merely for convenience and to give a general sense of the inventive concept. This description should be read to include one or more and the singular also includes the plural unless it is obvious that it is meant otherwise.
[0028] Further, use of the term“plurality” is meant to convey“more than one” unless expressly stated to the contrary.
[0029] As used herein any reference to "one embodiment" or "an embodiment" means that a particular element, feature, structure, or characteristic described in connection with the embodiment is included in at least one embodiment.
The appearances of the phrase "in one embodiment" in various places in the specification are not necessarily all referring to the same embodiment.
[0030] Circuitry, as used herein, may be analog and/or digital, components, or one or more suitably programmed microprocessors and associated hardware and software, or hardwired logic. Also, "components" may perform one or more functions. The term "component," may include hardware, such as a processor, an application specific integrated circuit (ASIC), or a field programmable gate array (FPGA), or a combination of hardware and software. Software includes one or more computer executable instructions that when executed by one or more component cause the component to perform a specified function. It should be understood that the algorithms described herein are stored on one or more non-transitory memory. Exemplary non-transitory memory includes random access memory, read only memory, flash memory or the like. Such non-transitory memory may be electrically based or optically based.
[0031] As used herein, the term“substantially” means that the subsequently described parameter, event, or circumstance completely occurs or that the subsequently described parameter, event, or circumstance occurs to a great extent or degree. For example, the term “substantially” means that the subsequently described parameter, event, or circumstance occurs at least 90% of the time, or at least 91 %, or at least 92%, or at least 93%, or at least 94%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99%, of the time, or means that the dimension or measurement is within at least 90%, or at least 91 %, or at least 92%, or at least 93%, or at least 94%, or at least 95%, or at least 96%, or at least
97%, or at least 98%, or at least 99%, of the referenced dimension or measurement. [0032] In accordance with one aspect, there are provided devices, systems, and processes for determining a presence of hemolysis in a sample. Advantageously, devices, systems, and processes described herein determine whether hemolysis has occurred in a sample based upon a colorimetry assessment of a portion of the sample.
[0033] In accordance with another aspect, there are provided devices, systems, and processes for a blood collection container having a hemolysis indicating feature.
[0034] In accordance with another aspect, there are provided blood collection devices, systems, accessories and processes having a plasma separating feature.
[0035] In accordance with another aspect, there are provided blood collection devices, systems, accessories, and processes having a hemolysis indicating feature.
[0036] Referring now to the Figures and in particular to Figure 1 , shown therein is a diagramatic view of a blood testing device 10 constructed in accordance with the present disclosure. In general, the blood testing device 10 includes a housing 12, an acoustic transducer 16, a reader 18, and a control unit 20 connected to the transducer 16 and the reader 18. The housing 12 is constructed of a fluid impermeable material so that the housing 12 can hold and contain a sample of blood containing blood cells, suspended within plasma. The housing 12 can be a syringe or a vacutainer, for example that can be used for collecting blood and transporting the blood for purposes of testing. The blood may be collected from an animal, such as a human, or a non-human (such as a cat, dog, cow, horse, fish, or the like). The acoustic transducer 16, the reader 18, and the control unit 20 may be located outside of the housing 12 as shown in FIG. 1 or inside the housing 12 (not shown). The acoustic transducer 16 selectively generates acoustic forces that are directed to the housing 12. In some embodiments, the acoustic transducer 16 can be tuned so as to provide a magnitude and/or frequency of acoustic forces so as to facilitate separation of the undamaged blood cells from the plasma and damaged blood cells.
The magnitude and/or frequency of the acoustic forces generated by the acoustic transducer 16 can be selected depending upon a size and/or construction of the housing 12, or composition of the blood sample within the housing 12. In one embodiment, the acoustic transducer 16 can be a piezoelectric element. At least a portion of the housing 12, adjacent to the transducer 16, is constructed of a material that functions to pass the acoustic forces generated by the acoustic transducer 16 into the sample contained within the housing 12. Exemplary materials that can be used to form the housing 12 include glass, crystal, and the like. Parts of the housing
12 away from the transducer 16 can be made of other materials such as plastic. The application of the acoustic forces into the sample by the acoustic transducer 16 causes the blood cells within the blood to move within the plasma to form a first zone
22 having an increased density or concentration of the blood cells than the blood contained prior to the application of the acoustic forces, and at least one second zone 24 being substantially only plasma, i.e. , substantially devoid of any undamaged blood cells. The reader 18 is positioned adjacent to the second zone 24 and functions to read at least one parameter of the plasma. In one embodiment, the reader 18 is an optical reader, such as a camera or photospectrometer having a field of view overlapping with the housing 12 such that the plasma within the second zone is visible to the reader 18. The optical reader 18 is positioned such that the second zone 24 is within the field of view. The control unit 20 selectively actuates / deactuates the acoustic transducer 16 to cause separation of the blood cells and plasma into the first zone 22 and the second zone 24. Then, in some embodiments, the control unit 20 actuates the reader 18 to capture information indicative of at least one parameter of the plasma. The information captured by the reader 18 is then transferred to the control unit 20 to determine a degree of hemolysis within the sample of blood. The control unit 20 can be constructed of circuitry and/or a combination of circuitry and software.
[0037] When the reader 18 is the optical reader, the degree of hemolysis can be determined by the control unit 20 based upon a colorimetric analysis of the sample. That is, when the sample is devoid of hemolysis and is illuminated with white light, the plasma will be substantially devoid of any color, i.e., the sample will be transparent. When hemolysis has occurred within the sample, the plasma will be pink when the plasma is illuminated with white light. By correlating the color of the plasma with predetermined colors indicative of an extent of hemolysis occurring within other samples, the extent of hemolysis within the sample can be determined. Depending upon a color of a backdrop, and/or color of illumination of the plasma, colors detected by the reader 18 indicative of an extent of hemolysis may differ.
[0038] Information indicative of an extent of hemolysis within the sample can be used to determine whether the blood has hemolysis.
[0039] FIG. 3 illustrates a blood testing device 40 constructed in accordance with one embodiment of the present disclosure. The blood testing device 40 is provided with a fluid container such as a syringe 42 or vacutainer having a fluid reservoir 44 for containing blood. The blood testing device 40 may also be provided with an acoustic transducer 46, an optical zone 48, and a bar code 50 which identifies the contents of the syringe 42 and can be correlated to specific patients. The acoustic transducer 46 may be provided with any suitable shape, such as planar, arcuate, or the like. In some embodiments, the acoustic transducer 46 may be provided with a shape to match a shape of the optical zone 48, or other section of the blood testing device 40 to be stimulated by the acoustic transducer 46. In such an embodiment, the blood testing device 40 allows the blood to be acoustically treated using the acoustic transducer 46 after which the blood may be analyzed using an optical reader or the human eye through the optical zone 48. Once a degree of hemolysis within the sample of blood has been determined, a decision can be made whether or not to continue with further testing of the sample of blood.
[0040] Referring now to Figures 4A-4C, shown therein is an embodiment of a blood testing device 70 and reader 71. The blood testing device 70 has a fluid housing 72, a fluid reservoir 74, a fluid treatment area 75, an optical zone 76, a treatment window 78, and a flow port 82. The reader 71 has a reading device 80, a flow path 82, and an analysis unit 84. In this embodiment of the blood testing device 70, a blood sample is contained in the fluid housing 72 and directed along the flow path 82 into the fluid treatment area 75 where the blood sample is directed to flow past the treatment window 78. The treatment window 78 is constructed of a material that functions to pass acoustic forces generated by an acoustic transducer into the blood sample contained within the fluid housing 72.
[0041] The reading device 80 is part of the analysis unit 84 and is provided with an acoustic transducer (not shown) and an optical reader (not shown) which operate as described above to acoustically treat the blood sample. The acoustic transducer may be provided with a planar shape so as to mate with the treatment window 78 of the blood testing device 70. The optical reader of the reading device 80 has a field of view directed to the optical zone 76 where the acoustically treated blood sample may be read. The analysis unit 84 actuates the acoustic transducer to acoustically treat the blood sample and move the blood cells away from the optical zone 76 such that only the plasma is visible in the optical zone 76. Then the optical reader captures an image of the plasma and any backdrop and sends the image to the analysis unit 84 for colorimetric analysis as discussed above. The analysis unit 84 may be provided with further blood analysis features (not shown) such as blood gas analysis which may further analyze the blood sample after it passes through the flow path 82. The reader 71 may be portable and have a housing 88 that includes a slot 90 sized and dimensioned to receive the blood testing device 70 such that the optical zone 76 is in the field of view of the optical reader and the treatment window overlaps with the acoustic transducer. The housing 88 can be provided in a variety of shapes such as in a shape of a hot dog bun, for instance. The analysis unit 84 can be supported in the housing 88 or be separate therefrom. For example, the reading device 80 can be provided with a wireless transceiver to communicate with the analysis unit 84. The analysis unit 84 may be constructed and function in a similar manner as the control unit 20 discussed above.
[0042] Figure 5 illustrates another variation of the reader 71 in which the fluid housing 72 of Figure 4 may be inserted into the housing 88 so that the blood sample may be acoustically treated and read by the reading device 80 as described above.
[0043] Referring now to Figure 6, a lateral flow blood testing device 100 constructed in accordance with the present disclosure is shown having a fluid housing 102, a first fluid reservoir 104, and a fluid treatment module 106. The fluid treatment module 106 of the lateral flow blood testing device 100 is provided with a lower portion 108, an upper portion 1 10, a second fluid reservoir 1 1 1 , a lateral flow strip 1 12, a fluid channel 1 14, a first fluid port 1 16, a second fluid port 1 18, an optical zone 120, and a bar code 122.
[0044] The lower portion 108 and the upper portion 1 10 of the fluid treatment module 106 are sealably connected to form the second fluid reservoir 1 1 1. When the fluid treatment module 106 is connected to the fluid housing 102, a blood sample may be transferred from the first fluid reservoir 104 to the second fluid reservoir 1 1 1. Once in the second fluid reservoir 1 1 1 , a portion of the blood sample may be directed through the second fluid port 1 18 into the fluid channel 1 14 where the blood sample passes through the lateral flow strip 1 12. Through capillary action (which may also be referred to as capillary flow), the lateral flow strip 1 12 causes the separation of undamaged blood cells and plasma in the blood sample as described more fully in U.S. Patent Application No. 15/317,748, the entirety of which is incorporated herein by reference. The plasma that has passed through the lateral flow strip 1 12 may then be analyzed in the optical zone 120 to determine a degree of hemolysis using an optical reader as described above or human eyes.
[0045] To facilitate directing the blood sample into the second fluid port 1 18, the first fluid port 1 16 may be temporarily sealed using a removable cap (not shown), for instance, that temporarily prevents movement of the blood sample through the first fluid port 1 16. When the blood sample has been analyzed using the lateral flow blood testing device 100, the cap may be removed and the blood sample may be allowed to pass through the first fluid port 1 16 to be used for further testing, for instance, as desired. [0046] As described above, the bar code 122 may be used to identify the blood sample, the patient the blood sample belongs too, the test to be performed, and the like.
[0047] Figure 7 illustrates a lateral flow blood testing device 140 having a fluid housing 142, a fluid treatment module 144, a first fluid reservoir 146, and a second fluid reservoir 148. The lateral flow blood testing device 140 is similar to the lateral flow blood testing device 100 described above, therefore, in the interest of brevity only the differences will be described herein. In the embodiment shown in Figure 7, the fluid treatment module 144 and the fluid housing 142 are integrated to form the lateral flow blood testing device 140.
[0048] Figure 8 illustrates a top plan view of a fluid treatment module 160 similar to fluid treatment modules 106 and 144. In this embodiment, the fluid treatment module 160 is provided with a fluid channel 162 that connects a first fluid port 164 with a second fluid port 166 to direct a flow of a blood sample into a fluid channel 168 for separation of the blood sample into at least two constituent parts as described above. The fluid channel 168 houses the lateral flow strip 1 12 that functions to separate the undamaged blood cells from the plasma so that the plasma and any color caused by damaged blood cells is visible in the optical zone 120.
[0049] Referring now to Figure 9, shown therein is another embodiment of a lateral flow blood testing device 180 having a fluid housing 182, a fluid reservoir 184, and a fluid treatment module 186. The fluid treatment module 186 of the lateral flow blood testing device 180 is provided with a lower portion 188, an upper portion 190, a second fluid reservoir 192, and a lateral flow membrane 194. [0050] The lower portion 188 and the upper portion 190 of the fluid treatment module 186 are sealably connected to form the second fluid reservoir 192. When the fluid treatment module 186 is connected to the fluid housing 182, a blood sample may be transferred from the first fluid reservoir 184 to the second fluid reservoir 192. As the blood sample is transferred from the first fluid reservoir 184 to the second fluid reservoir 192 the blood sample passes through the lateral flow membrane 194 and the blood sample is separated into at least two constituent parts, i.e., undamaged blood cells remain in the first fluid reservoir 184 and plasma with any damaged blood cells pass through the lateral flow membrane 194 and into the second fluid reservoir 192.
[0051] At least the lower portion 188 of the fluid treatment module 186 is constructed of an optically clear material which allows the plasma that has passed through the lateral flow membrane 194 to be colorimetrically analyzed in the second fluid reservoir 192 using an optical reader as described above or human eyes.
[0052] Also shown in Figure 9 is a probe 196 which may be attached to or part of a blood analysis machine (not shown) such as a blood gas analyzer. Where whole blood is needed for analysis, the probe 196 may be passed through a fluid port 198 in the fluid treatment module 186, through the second fluid reservoir 192, and through the lateral flow membrane 194 into the first fluid reservoir 184 where the blood sample has not been separated.
[0053] Figure 10 illustrates another version of a lateral flow blood testing device 200 having a fluid housing 202, a fluid treatment module 204, a first fluid reservoir 206, a second fluid reservoir 208, a lateral flow membrane 210, and a fluid port 214. The lateral flow blood testing device 200 is similar to the lateral flow blood testing device 180 described above, therefore, in the interest of brevity only the differences will be described herein. In the embodiment shown in Figure 10, the fluid treatment module 204 and the fluid housing 202 are integrated into a unitary structure, rather than removably connected to form the lateral flow blood testing device 200.
[0054] A probe 212 is also shown which may be attached to or part of a blood analysis machine (not shown) such as a blood gas analyzer. Where whole
(unseparated) blood is needed for analysis, the probe 212 may be passed through the fluid port 214 in the fluid treatment module 204, through the second fluid reservoir 206, and through the lateral flow membrane 210 into the first fluid reservoir 206 where the blood sample has not been separated.
[0055] Referring now to Figures 1 1-13, shown therein is yet another version of a blood testing device 240 similar to the blood testing device 70 shown in Figure 4 that can be read by the reader 71. In the interest of brevity, only the differences will be described in detail herein. The blood testing device 240 is provided with a fluid housing 242 a fluid reservoir 244, a fluid treatment area 245, an optical zone 246, a treatment window 248, a flow path 252, a gate 254 having a port 256, and a gate guide channel 258.
[0056] When the gate 254 is in a first position (shown in Figure 12), the flow path 252 is restricted such that a blood sample in the flow path 252 stops in the optical zone 246 where the sample may be acoustically treated to move undamaged blood cells away from the plasma adjacent to the optical zone 246 and read with the reader 71 as described above. [0057] Once the blood sample has been analyzed the gate 254 may be moved to a second position (shown in Figure 13), which moves the port 256 into the flow path 252 allowing the blood sample to pass.
[0058] Referring now to Figures 14-16, shown therein is yet another version of a blood testing device 280 similar to the blood testing devices 70 and 240 shown in Figures 4 and 1 1-13, respectively that can be read by the reader 71. In the interest of brevity, only the differences will be described in detail herein. The blood testing device 280 is provided with a fluid housing 282 a fluid reservoir 284, a fluid treatment area 285, an optical zone 286, a treatment window 288, a first flow path 292, a second flow path 294, a gate 296 having a port 298, and a gate guide channel 300.
[0059] When the gate 296 is in a first position (shown in Figure 15), a blood sample is directed into the first flow path 292 such that the blood sample stops in the optical zone 286 where the blood sample may be acoustically treated and read with the reading device 80 as described above.
[0060] Once the blood sample has been analyzed the gate 296 may be moved to a second position (shown in Figure 16), which moves the port 298 into the second flow path 294 allowing the blood sample to pass through the second flow path 294.
[0061] From the above description, it is clear that the inventive concepts disclosed herein is well adapted to carry out the objects and to attain the advantages mentioned herein as well as those inherent in the inventive concepts disclosed herein. While presently preferred embodiments of the inventive concepts disclosed herein have been described for purposes of this disclosure, it will be understood that numerous changes may be made which will readily suggest themselves to those skilled in the art and which are accomplished within the scope and coverage of the inventive concepts disclosed and claimed herein.

Claims

What is claimed is:
1. A blood testing assembly, comprising:
a blood testing device, comprising:
a housing constructed of a fluid impermeable material;
a treatment window formed in the housing, the treatment window constructed of a material capable of passing acoustic forces into the housing;
an optical zone formed in the treatment window of the housing, the optical zone constructed of a material that allows a colorimetric analysis of a blood sample positioned within the housing, and located adjacent to the optical zone; and
a reader, comprising:
an acoustic transducer position to selectively generate acoustic forces directed through the treatment window of the housing and into the blood sample; and
a control unit for selectively actuating and deactuating the acoustic transducer.
2. A method, comprising:
separating blood cells from plasma within a blood sample into a first zone containing plasma and blood cells, and a second zone containing plasma and being substantially devoid of blood cells; and colorimetrically analyzing the plasma within the second zone to determine a degree of hemolysis within the blood sample.
PCT/US2019/064623 2018-12-07 2019-12-05 Solution collection device with evaluation element Ceased WO2020118018A1 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
EP19893876.3A EP3890594A4 (en) 2018-12-07 2019-12-05 SOLUTION COLLECTION DEVICE WITH EVALUATION ELEMENT
MX2021006612A MX2021006612A (en) 2018-12-07 2019-12-05 SOLUTION COLLECTION DEVICE WITH EVALUATION ELEMENT.
JP2021531951A JP2022511512A (en) 2018-12-07 2019-12-05 Solution sampling device containing evaluation elements
CA3122235A CA3122235A1 (en) 2018-12-07 2019-12-05 Solution collection device with evaluation element
US17/299,816 US12332234B2 (en) 2018-12-07 2019-12-05 Solution collection device with evaluation element
IL283691A IL283691A (en) 2018-12-07 2021-06-03 Solution collection device with evaluation element
US19/214,650 US20250283868A1 (en) 2018-12-07 2025-05-21 Solution collection device with evaluation element

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862776825P 2018-12-07 2018-12-07
US62/776,825 2018-12-07

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US17/299,816 A-371-Of-International US12332234B2 (en) 2018-12-07 2019-12-05 Solution collection device with evaluation element
US19/214,650 Continuation US20250283868A1 (en) 2018-12-07 2025-05-21 Solution collection device with evaluation element

Publications (1)

Publication Number Publication Date
WO2020118018A1 true WO2020118018A1 (en) 2020-06-11

Family

ID=70974865

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2019/064623 Ceased WO2020118018A1 (en) 2018-12-07 2019-12-05 Solution collection device with evaluation element
PCT/US2019/064627 Ceased WO2020118021A1 (en) 2018-12-07 2019-12-05 Device with a fluid component assessment feature

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/US2019/064627 Ceased WO2020118021A1 (en) 2018-12-07 2019-12-05 Device with a fluid component assessment feature

Country Status (7)

Country Link
US (4) US12332234B2 (en)
EP (2) EP3890594A4 (en)
JP (2) JP2022510440A (en)
CA (2) CA3122260A1 (en)
IL (2) IL283690A (en)
MX (2) MX2021006613A (en)
WO (2) WO2020118018A1 (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023019087A1 (en) * 2021-08-12 2023-02-16 Siemens Healthcare Diagnostics Inc. Apparatus and method for transferring a fluid sample from a fluid sample collection apparatus to a liquid sample analyzer
US11959907B2 (en) 2015-01-12 2024-04-16 Instrumentation Laboratory Company Spatial separation of particles in a particle containing solution for biomedical sensing and detection
USD1043975S1 (en) 2021-08-12 2024-09-24 Siemens Healthcare Diagnostics Inc. Fluid transfer adapter
US12326442B2 (en) 2018-12-07 2025-06-10 Siemens Healthcare Diagnostics Inc. Device with a fluid component assessment feature
US12399169B2 (en) 2019-07-19 2025-08-26 Siemens Healthcare Diagnostics Inc. Tangent flow hemolysis detection blood testing device
US12584902B2 (en) 2023-12-10 2026-03-24 Instrumentation Laboratory Company Acoustic separation of a test sample

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7345057B2 (en) * 2019-08-29 2023-09-14 シーメンス・ヘルスケア・ダイアグノスティックス・インコーポレイテッド Devices and methods for evaluating fluid samples with disposable multi-analyte consumables
EP4189392A4 (en) * 2020-08-17 2024-01-03 RJS Mediagnostix Fluid testing device
JP7577301B2 (en) * 2020-09-23 2024-11-05 株式会社Provigate Liquid sample processing device
GB202019998D0 (en) * 2020-12-17 2021-02-03 Clinical Design And Tech Limited Apparatus for testing a liquid specimen using suction
GB2616214B (en) * 2020-12-17 2024-10-09 Clinical Design Tech Limited Apparatus for testing a liquid specimen using suction
CA3227618A1 (en) 2021-08-12 2023-02-16 Janine COX Apparatus and method for transferring a fluid sample from a fluid sample collection apparatus to a liquid sample analyzer
US20260118257A1 (en) * 2023-01-27 2026-04-30 Siemens Healthcare Diagnostics Inc. Apparatus and method for testing blood
WO2025240830A1 (en) * 2024-05-16 2025-11-20 Haemonetics Corporation System for screening source plasma

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120086938A1 (en) * 2009-07-13 2012-04-12 Foss Analytical A/S Analysis of an Acoustically Separated Liquid
US20120232803A1 (en) * 2011-02-15 2012-09-13 Hemosonics Llc Characterization of blood hemostasis and oxygen transport parameters
US20160202237A1 (en) 2015-01-12 2016-07-14 Instrumentation Laboratory Company Spatial Separation of Particles in a Particle Containing Solution for Biomedical Sensing and Detection
US20170299481A1 (en) * 2016-04-14 2017-10-19 Covaris, Inc. Sample holder for acoustic treatment
WO2018065626A1 (en) 2016-10-07 2018-04-12 Acousort Ab Method and system for optical or electrical measurements in disperse fluids

Family Cites Families (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US484487A (en) 1892-10-18 Charles w
US3954623A (en) 1974-05-28 1976-05-04 Johnson & Johnson Blood filtration unit
DE3616062A1 (en) 1986-05-13 1987-11-19 Fresenius Ag METHOD FOR DETERMINING GAS PARTIAL PRESSURES IN BLOOD AND DEVICE FOR IMPLEMENTING THE METHOD
US5125415A (en) 1990-06-19 1992-06-30 Smiths Industries Medical Systems, Inc. Syringe tip cap with self-sealing filter
USRE39457E1 (en) * 1991-04-18 2007-01-02 Lamina, Inc. Liquid specimen container and attachable testing modules
US5330420A (en) 1992-01-13 1994-07-19 Therakos, Inc. Hemolysis detector
US5460974A (en) 1992-10-13 1995-10-24 Miles Inc. Method of assaying whole blood for HDL cholesterol
US6196998B1 (en) 1994-12-12 2001-03-06 Becton Dickinson And Company Syringe and tip cap assembly
US5922210A (en) 1995-06-16 1999-07-13 University Of Washington Tangential flow planar microfabricated fluid filter and method of using thereof
CN2240724Y (en) 1995-08-09 1996-11-20 中国科学院大连化学物理研究所 Plasma separator for clinical blood analysis
JPH09196911A (en) 1996-01-19 1997-07-31 Fuji Photo Film Co Ltd Blood filter unit
JP3664328B2 (en) 1996-01-19 2005-06-22 富士写真フイルム株式会社 Method for preparing plasma or serum sample
US5962215A (en) * 1996-04-05 1999-10-05 Mercury Diagnostics, Inc. Methods for testing the concentration of an analyte in a body fluid
JP3685283B2 (en) 1997-02-13 2005-08-17 富士写真フイルム株式会社 Plasma collection tool
JP3903098B2 (en) 1997-07-18 2007-04-11 富士フイルム株式会社 Blood filtration method
JPH11237378A (en) 1998-02-19 1999-08-31 Fuji Photo Film Co Ltd Method for separating serum from whole blood
US6220453B1 (en) 1998-04-07 2001-04-24 Fuji Photo Film Co., Ltd. Blood filter unit
US6217540B1 (en) 1998-07-10 2001-04-17 Fuji Photo Film Co., Ltd. Blood filter cartridge
JP2000180443A (en) 1998-12-15 2000-06-30 Fuji Photo Film Co Ltd Recovery method of haemofiltration residue
JP2000180442A (en) 1998-12-15 2000-06-30 Fuji Photo Film Co Ltd Hemofilter
JP3715123B2 (en) 1998-12-28 2005-11-09 富士写真フイルム株式会社 Blood filtration unit
JP2000202023A (en) 1999-01-19 2000-07-25 Fuji Photo Film Co Ltd Blood filter
JP3990505B2 (en) 1999-02-02 2007-10-17 富士フイルム株式会社 Blood component analysis method
US6936473B2 (en) 2000-01-05 2005-08-30 Leisure, Inc. Method of preparing a biological sample for quantification
JP2001321368A (en) 2000-05-16 2001-11-20 Fuji Photo Film Co Ltd Plasma taking tool
US6659288B2 (en) 2000-05-16 2003-12-09 Fuji Photo Film Co., Ltd. Plasma- or serum-collecting device
US20020036170A1 (en) 2000-08-11 2002-03-28 Harvey Michael A. Lateral flower plasma separation device
DE10046173C2 (en) 2000-09-08 2003-04-03 Inst Chemo Biosensorik Device and method for separating undissolved components from biological liquids
US7323144B2 (en) 2002-03-18 2008-01-29 Leisure, Inc. Apparatus for separating biological sample and separating method of the same
JP2003287532A (en) 2002-03-28 2003-10-10 Fuji Photo Film Co Ltd Blood test unit
DK1549385T3 (en) 2002-06-25 2020-02-10 Radiometer Medical Aps TEST TAKING HOOD
KR101005970B1 (en) 2002-11-19 2011-01-05 가부시키가이샤 아이 디자인 Filter device using plasma or serum separation membrane and plasma or serum separation membrane
EP1697743B1 (en) 2003-12-24 2009-03-11 Becton, Dickinson and Company Plasma on demand tube
US20050227370A1 (en) 2004-03-08 2005-10-13 Ramel Urs A Body fluid analyte meter & cartridge system for performing combined general chemical and specific binding assays
US20080003141A1 (en) 2004-04-30 2008-01-03 Kazuya Iketani Sample Analyzing Tool
JP2006038512A (en) 2004-07-23 2006-02-09 Fuji Photo Film Co Ltd Blood filtering glass fiber filter, blood filtering implement and blood analyzing element
JP2006038525A (en) 2004-07-23 2006-02-09 Fuji Photo Film Co Ltd Liquid filtering instrument and dry analyzing element
WO2007000986A1 (en) 2005-06-27 2007-01-04 Sekisui Chemical Co., Ltd. Blood-separating filter device and vacuum sampling tube
JP3890066B2 (en) 2005-06-27 2007-03-07 積水化学工業株式会社 Blood separation instrument and blood separation device
DE202006007817U1 (en) 2006-05-16 2006-07-27 Pfaff, Dieter Separator for extracting serum from blood sample in separation strip, comprising hinged upper and lower parts with projections for pressing serum from the strip on folding the parts together
US20080017577A1 (en) 2006-07-21 2008-01-24 Becton, Dickinson And Company Membrane-based Double-layer Tube for Sample Collections
NL1033365C2 (en) 2007-02-09 2008-08-12 Medavinci Dev B V Device and method for separating and analyzing blood.
KR100912530B1 (en) 2007-11-13 2009-08-18 한국전자통신연구원 Disposable multilayer plasma separation filter element
US8535617B2 (en) 2007-11-30 2013-09-17 Kimberly-Clark Worldwide, Inc. Blood cell barrier for a lateral flow device
JPWO2009110089A1 (en) 2008-03-07 2011-07-14 株式会社ティー・ワイ・エー Body fluid component analyzer
US20100111763A1 (en) 2008-03-18 2010-05-06 Kahn Laurence H Examination Device for Blood Detection
US8865003B2 (en) * 2008-09-26 2014-10-21 Abbott Laboratories Apparatus and method for separation of particles suspended in a liquid from the liquid in which they are suspended
JP5608943B2 (en) 2009-03-31 2014-10-22 マイクロ化学技研株式会社 Plasma separation apparatus and method
WO2010129302A1 (en) 2009-04-28 2010-11-11 Innovative Laboratory Technologies, Inc. Lateral-flow immuno-chromatographic assay devices
EP2264453B1 (en) 2009-06-17 2013-04-03 Leukocare Ag Method for filtering blood
EP3974838B1 (en) 2009-08-13 2026-04-22 Siemens Healthcare Diagnostics Inc. Methods for ascertaining physical dimensions in liquid samples and containers to be analyzed by a clinical analyzer
CN102481576B (en) 2009-09-17 2014-12-24 霍夫曼-拉罗奇有限公司 Sample input device for inputting liquid samples (clot catcher)
WO2011155897A1 (en) 2010-06-10 2011-12-15 Hemcheck Sweden Aktiebolag Arrangement for detection of hemolysis
CN103229053B (en) 2010-07-27 2015-06-24 西北大学 Device and method for filtering plasma
US9261494B2 (en) 2011-01-06 2016-02-16 Samsung Electronics Co., Ltd. Biosensor cartridge
US8727129B2 (en) * 2011-08-16 2014-05-20 Lawrence Livermore National Security, Llc. Microfluidic ultrasonic particle separators with engineered node locations and geometries
US9731062B2 (en) * 2011-08-29 2017-08-15 The Charles Stark Draper Laboratory, Inc. System and method for blood separation by microfluidic acoustic focusing
SE536634C2 (en) 2011-12-09 2014-04-15 Hemcheck Sweden Ab Device for detecting hemolysis
WO2013096817A2 (en) 2011-12-23 2013-06-27 Abbott Point Of Care Inc Integrated test device for optical detection of microarrays
JP5901012B2 (en) * 2012-02-13 2016-04-06 国立大学法人 東京医科歯科大学 Blood information measuring method and apparatus
WO2014019255A1 (en) 2012-07-31 2014-02-06 上海科华检验医学产品有限公司 Vacuum blood collection pipe capable of directly separating serum and method thereof
EP2695655A1 (en) 2012-08-09 2014-02-12 F. Hoffmann-La Roche AG Multi-part device for extracting plasma from blood
EP2695652A1 (en) 2012-08-09 2014-02-12 F. Hoffmann-La Roche AG System for separating plasma from blood
US9427707B2 (en) 2012-08-10 2016-08-30 Jean I. Montagu Filtering blood
CA2909229C (en) 2013-04-15 2020-08-18 Becton, Dickinson And Company Biological fluid collection device and biological fluid separation and testing system
ES2654897T3 (en) 2013-04-15 2018-02-15 Becton, Dickinson And Company System of separation and analysis of biological fluids
EP3135377A1 (en) 2013-04-15 2017-03-01 Becton, Dickinson and Company Biological fluid collection device and biological fluid separation and testing system
DE102013010724A1 (en) 2013-06-27 2014-12-31 Mann+Hummel Gmbh A whole blood plastic hollow fiber membrane filter medium and use thereof for separating blood plasma / serum from whole blood
DE102013010735A1 (en) 2013-06-27 2015-01-15 Mann + Hummel Gmbh A ceramic whole blood hollow fiber membrane filter medium and use thereof for separating blood plasma / serum from whole blood
WO2015006515A1 (en) 2013-07-09 2015-01-15 Sri International Biomarker panel for dose assessment of radiation injury and micro plasma filter
DE102013012676A1 (en) 2013-07-31 2015-02-05 Mann + Hummel Gmbh Device for crossflow filtration
KR20150039051A (en) 2013-10-01 2015-04-09 삼성전자주식회사 Blood filter device separating plasma or serum from blood and the use thereof
DE102013017035A1 (en) 2013-10-15 2015-04-16 Mann + Hummel Gmbh Blood filter device
WO2015061299A2 (en) * 2013-10-21 2015-04-30 Northeastern University Point-of-care immunosensing device for multi-biomarker detection
ES2949108T3 (en) 2013-12-20 2023-09-25 Spot Bioscience Llc Sampling apparatus for whole blood separation
CN106879252B (en) 2014-06-10 2020-07-17 德克斯特里蒂诊断公司 Devices and methods for collecting and stabilizing biological samples
WO2015191450A1 (en) * 2014-06-13 2015-12-17 Siemens Healthcare Diagnostics Inc. Detection of hemolysis using a chromatographic detection pad
WO2016019113A1 (en) 2014-08-01 2016-02-04 Siemens Healthcare Diagnostics Inc. Vacuum-assisted plasma separation
EP3201624B1 (en) 2014-09-30 2020-03-11 Siemens Healthcare Diagnostics Inc. Hemolysis detection device, system and method
WO2016073415A2 (en) 2014-11-04 2016-05-12 Wainamics, Inc. Microscale plasma separator
US20160258937A1 (en) * 2015-03-06 2016-09-08 J. Kent ELLINGTON Urine test device incorporating urinary catheter or urinary bag attachment device and associated method of use
JP6820865B2 (en) 2015-04-29 2021-01-27 ペルキネルマー ヘルス サイエンシーズ， インコーポレイテッド Sample collection and delivery device
KR102111903B1 (en) 2015-07-06 2020-05-15 후지필름 가부시키가이샤 Blood analysis method and blood testing kit
KR20180016513A (en) 2015-07-06 2018-02-14 후지필름 가부시키가이샤 Blood test kit and analyzing method using the same
JP6495768B2 (en) 2015-07-06 2019-04-03 富士フイルム株式会社 Blood analysis method and blood test kit
DE102015112343A1 (en) 2015-07-29 2017-02-02 Westfälische Wilhelms-Universität Münster Apparatus and method for processing body fluids
ES2857873T3 (en) 2015-09-01 2021-09-29 Becton Dickinson Co Depth filtration device to separate phases of samples
WO2017044888A1 (en) 2015-09-09 2017-03-16 Theranos, Inc. Methods and devices for sample collection and sample separation
SE539853C2 (en) 2016-02-03 2017-12-19 Hemcheck Sweden Ab An arrangement for collection and separation of a body fluidfor purposes of analysis and a method relating thereto
WO2017143323A1 (en) * 2016-02-19 2017-08-24 Insight Instruments, Inc. Assay systems for point of care detection of ocular analytes
AU2017227802B2 (en) * 2016-03-02 2020-11-12 Becton, Dickinson And Company Biological fluid separation device
EP3458839A1 (en) * 2016-05-20 2019-03-27 Instrumentation Laboratory Company Evanescent hemolysis detection
EP3469358B1 (en) * 2016-06-09 2025-10-22 Becton, Dickinson and Company Biological fluid separation device
EP3541515A1 (en) 2016-11-16 2019-09-25 Quidel Corporation Device for whole blood separation
CN108732001B (en) 2017-04-24 2021-03-05 光宝电子(广州)有限公司 Plasma and blood cell separation device and separation method thereof
EP4241888B1 (en) 2017-06-08 2025-08-27 Becton, Dickinson and Company Biological fluid separation device
WO2019025914A1 (en) 2017-07-31 2019-02-07 Gupta Nalini K Plasma separation device
MX2021006613A (en) 2018-12-07 2021-07-07 Siemens Healthcare Diagnostics Inc Device with a fluid component assessment feature.
JP7349502B2 (en) 2019-03-12 2023-09-22 シーメンス・ヘルスケア・ダイアグノスティックス・インコーポレイテッド Hemolysis detection blood test device
CA3147512C (en) 2019-07-19 2024-04-02 Siemens Healthcare Diagnostics Inc. Tangent flow hemolysis detection blood testing device

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120086938A1 (en) * 2009-07-13 2012-04-12 Foss Analytical A/S Analysis of an Acoustically Separated Liquid
US20120232803A1 (en) * 2011-02-15 2012-09-13 Hemosonics Llc Characterization of blood hemostasis and oxygen transport parameters
US20160202237A1 (en) 2015-01-12 2016-07-14 Instrumentation Laboratory Company Spatial Separation of Particles in a Particle Containing Solution for Biomedical Sensing and Detection
US20170299481A1 (en) * 2016-04-14 2017-10-19 Covaris, Inc. Sample holder for acoustic treatment
WO2018065626A1 (en) 2016-10-07 2018-04-12 Acousort Ab Method and system for optical or electrical measurements in disperse fluids

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11959907B2 (en) 2015-01-12 2024-04-16 Instrumentation Laboratory Company Spatial separation of particles in a particle containing solution for biomedical sensing and detection
US12072329B2 (en) 2015-01-12 2024-08-27 Instrumentation Laboratory Company Spatial separation of particles in a particle containing solution for biomedical sensing and detection
US12092630B2 (en) 2015-01-12 2024-09-17 Instrumentation Laboratory Company Spatial separation of particles in a particle containing solution for biomedical sensing and detection
US12326442B2 (en) 2018-12-07 2025-06-10 Siemens Healthcare Diagnostics Inc. Device with a fluid component assessment feature
US12399169B2 (en) 2019-07-19 2025-08-26 Siemens Healthcare Diagnostics Inc. Tangent flow hemolysis detection blood testing device
WO2023019087A1 (en) * 2021-08-12 2023-02-16 Siemens Healthcare Diagnostics Inc. Apparatus and method for transferring a fluid sample from a fluid sample collection apparatus to a liquid sample analyzer
USD1043975S1 (en) 2021-08-12 2024-09-24 Siemens Healthcare Diagnostics Inc. Fluid transfer adapter
US12584902B2 (en) 2023-12-10 2026-03-24 Instrumentation Laboratory Company Acoustic separation of a test sample

Also Published As

Publication number Publication date
US20220018827A1 (en) 2022-01-20
JP2022510440A (en) 2022-01-26
MX2021006612A (en) 2021-07-07
CA3122260A1 (en) 2020-06-11
EP3890594A4 (en) 2022-02-16
IL283690A (en) 2021-07-29
US12332234B2 (en) 2025-06-17
EP3890594A1 (en) 2021-10-13
MX2021006613A (en) 2021-07-07
EP3890871A4 (en) 2022-01-26
US12326442B2 (en) 2025-06-10
US20250264453A1 (en) 2025-08-21
JP2022511512A (en) 2022-01-31
US20220023857A1 (en) 2022-01-27
IL283691A (en) 2021-07-29
WO2020118021A1 (en) 2020-06-11
CA3122235A1 (en) 2020-06-11
EP3890871A1 (en) 2021-10-13
US20250283868A1 (en) 2025-09-11

Similar Documents

Publication Publication Date Title
US20250283868A1 (en) Solution collection device with evaluation element
JP6927465B2 (en) Model-based methods and equipment for classifying interfering factors in specimens
EP3408648B1 (en) Methods and apparatus for imaging a specimen container and/or specimen using multiple exposures
EP2715611B1 (en) Cell counting systems and methods
US8911679B2 (en) Color-based reaction testing of biological materials
US9983139B2 (en) Modular illumination and sensor chamber
US20050203353A1 (en) Multiple purpose, portable apparatus for measurement, analysis and diagnosis
JP7057820B2 (en) Specimen evaluation method and sample evaluation device using hyperspectral imaging
US9945789B2 (en) Multiple analyte detection systems and methods of detecting multiple analytes
Woodburn et al. Analysis of paper-based colorimetric assays with a smartphone spectrometer
US20180299376A1 (en) Modular illumination and sensor chamber
CN106233308A (en) Systems, devices and methods for sample integrity verification
CN107219221A (en) Drugs Checkout Gear and detection method
EP2956575B1 (en) Reduction of false positives on reagent test devices
EP3351304A1 (en) Test cup for analysing a fluid specimen, device for analysing a fluid specimen,kit of parts, and method
JP2022525096A (en) Hemolysis detection blood test device
CN213957408U (en) Blood protein analysis device
CN113950620B (en) Apparatus and process for screening biological samples
JP2007285922A (en) Clinical blood test using near infrared light
RU237419U1 (en) Device for multiplex analysis of biomarkers by immunofluorescence analysis
CN210514070U (en) Device for rapidly determining paralytic shellfish poisoning in mussel
KR20230053102A (en) Diagnosis kit for qualitative test, and automated apparatus for comprising the kit
CN121917790A (en) Sample analyzer and sample analysis method

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19893876

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2021531951

Country of ref document: JP

Kind code of ref document: A

Ref document number: 3122235

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2019893876

Country of ref document: EP

Effective date: 20210707

WWG Wipo information: grant in national office

Ref document number: 17299816

Country of ref document: US